Advances in Viral Infections Management to Fuel Varicella Zoster Infection Treatment Market Growth, Worth US$ 2.0 Billion by 2028 | FMI

The global market for varicella zoster infection treatment was valued at over US$ 1.5 billion in 2020, and it is projected to grow at a steady Compound Annual Growth Rate (CAGR) of 4.1%, reaching a market value of US$ 2.0 billion by 2028, as per forecasts by Future Market Insights. In 2022, acyclovir is anticipated to dominate the global varicella zoster infection treatment market, accounting for more than 55.7% of the market share.

Acute varicella infection can give rise to various complications, including secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, as well as viral and bacterial pneumonia. The epidemiology of varicella appears to be influenced by climate conditions. In temperate climates, around 90% of individuals are infected before reaching adolescence. Conversely, in tropical climates, Varicella Zoster Virus (VZV) infections typically occur later in life, with adults being more susceptible than children.

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population.

Claim your complimentary report with captivating visuals
https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Key Players:

• Novartis AG,
• Pfizer Inc.,
• Abbott Laboratories,
• Sun Pharmaceuticals Industries Ltd.,
• Valeant Pharmaceuticals International Inc.,
• Teva Pharmaceutical Industries Ltd.,
• Dr. Reddy’s Laboratories, ltd.,
• Mylan N.V.  and
• GlaxoSmithKline

Ready to Explore Our Methodology? Click Now!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-6466

Varicella Zoster Infection Treatment – Market Segmentation – by Category

By Drug Type:

• Acyclovir
• Valacyclovir
• Famciclovir

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube